Praxis Precision Medicines Revenue and Competitors
Estimated Revenue & Valuation
- Praxis Precision Medicines's estimated annual revenue is currently $25.9M per year.
- Praxis Precision Medicines's estimated revenue per employee is $266,856
- Praxis Precision Medicines's total funding is $223.1M.
- Praxis Precision Medicines's current valuation is $786.3M. (January 2022)
Employee Data
- Praxis Precision Medicines has 97 Employees.
- Praxis Precision Medicines grew their employee count by -25% last year.
Praxis Precision Medicines's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Biology | Reveal Email/Phone |
2 | VP Clinical Development, Psychiatry | Reveal Email/Phone |
3 | VP, Head Clinical Development Operations | Reveal Email/Phone |
4 | General Counsel | Reveal Email/Phone |
5 | VP, Head Data Sciences | Reveal Email/Phone |
6 | VP, Finance/Principal Accounting Officer | Reveal Email/Phone |
7 | Head External CMC | Reveal Email/Phone |
8 | Chief Technical Operations Officer | Reveal Email/Phone |
9 | Chief Business Officer | Reveal Email/Phone |
10 | Sr. Director Procurement & Strategic Sourcing | Reveal Email/Phone |
Praxis Precision Medicines Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Praxis Precision Medicines?
Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. We are applying insights into genetic mutations resulting in neuronal imbalance to enable us to develop a pipeline addressing prevalent psychiatric and neurologic conditions and rare diseases. We have established a broad portfolio, including five disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes.
keywords:N/A
$223.1M
Total Funding
97
Number of Employees
$25.9M
Revenue (est)
-25%
Employee Growth %
$786.3M
Valuation
N/A
Accelerator
Praxis Precision Medicines News
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company...
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS...
PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study PRAX-114 was well tolerated in Phase 2a PMD study with no change in overall safety profile CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a ...
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monothe ...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results Expands pipeline with new indications for PRAX-114 and PRAX-944 PRAX-114 Phase 2 trial for treatment of post-traumatic stress disorder to initiate in 2H21 PRAX-114 Phase 2 trial for treatment ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $26.2M | 97 | -3% | N/A |
#2 | $13.6M | 97 | -9% | $77.3M |
#3 | $16.5M | 97 | -8% | $27.6M |
#4 | $26.2M | 97 | 5% | N/A |
#5 | $26.5M | 98 | 10% | N/A |